Association of Genomic Instability with HbA1c levels and Medication in Diabetic Patients
Annemarie Grindel, Helmut Brath, Armen Nersesyan, Siegfried Knasmueller, Karl-Heinz Wagner, Annemarie Grindel, Helmut Brath, Armen Nersesyan, Siegfried Knasmueller, Karl-Heinz Wagner
Abstract
Diabetes Mellitus type 2 (DM2) is associated with increased cancer risk. Instability of the genetic material plays a key role in the aetiology of human cancer. This study aimed to analyse genomic instability with the micronucleus cytome assay in exfoliated buccal cells depending on glycated haemoglobin (HbA1c) levels and medication in 146 female DM2 patients. The occurrence of micronuclei was significantly increased in DM2 patients compared to healthy controls. Furthermore, it was doubled in DM2 patients with HbA1c > 7.5% compared to subjects with HbA1c ≤ 7.5%. Positive correlations were found between micronuclei frequencies and HbA1c as well as fasting plasma glucose. Patients under insulin treatment showed a two-fold increase in micronuclei frequencies compared to subjects under first-line medication (no drugs or monotherapy with non-insulin medication). However, after separation of HbA1c (cut-off 7.5%) only patients with severe DM2 characterised by high HbA1c and insulin treatment showed higher micronuclei frequencies but not patients with insulin treatment and low HbA1c. We demonstrated that the severity of DM2 accompanied by elevated micronuclei frequencies predict a possible enhanced cancer risk among female DM2 patients. Therapy, therefore, should focus on a strict HbA1c control and personalised medical treatments.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
- Inzucchi S. E. et al.. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577–1596, doi: 10.1007/s00125-012-2534-0 (2012).
- Inzucchi S. E. et al.. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58, 429–442, doi: 10.1007/s00125-014-3460-0 (2015).
- Inzucchi S. E. & Majumdar S. K. Current Therapies for the Medical Management of Diabetes. Obstet. Gynecol. 127, 780–794, doi: 10.1097/aog.0000000000001332 (2016).
- American Diabetes Association. Glycemic targets. Diabetes Care 38 Suppl, S33–40, doi: 10.2337/dc15-S009 (2015).
- Zoungas S. et al.. Association of HbA(1c) levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55, 636–643, doi: 10.1007/s00125-011-2404-1 (2012).
- de Beer J. C. & Liebenberg L. Does cancer risk increase with HbA(1c), independent of diabetes? Br. J. Cancer 110, 2361–2368, doi: 10.1038/bjc.2014.150 (2014).
- Goto A. et al.. High hemoglobin A1c levels within the non-diabetic range are associated with the risk of all cancers. Int. J. Cancer 138, 1741–1753, doi: 10.1002/ijc.29917 (2016).
- Hua F., Yu J. J. & Hu Z. W. Diabetes and cancer, common threads and missing links. Cancer Lett. 374, 54–61, doi: 10.1016/j.canlet.2016.02.006 (2016).
- Ferguson L. R. et al.. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin. Cancer Biol. 35, S5–S24, doi: 10.1016/j.semcancer.2015.03.005 (2015).
- Shen Z. Y. Genomic instability and cancer: an introduction. J. Mol. Cell Biol. 3, 1–3, doi: 10.1093/jmcb/mjq057 (2011).
- Thomas P. et al.. Buccal micronucleus cytome assay. Nat. Protoc. 4, 825–837, doi: 10.1038/nprot.2009.53 (2009).
- Bolognesi C., Knasmueller S., Nersesyan A., Thomas P. & Fenech M. The HUMNxl scoring criteria for different cell types and nuclear anomalies in the buccal micronucleus cytome assay - An update and expanded photogallery. Mutat. Res.-Rev. Mutat. Res. 753, 100–113, doi: 10.1016/j.mrrev.2013.07.002 (2013).
- Mullner E. et al.. Nuclear anomalies in exfoliated buccal cells in healthy and diabetic individuals and the impact of a dietary intervention. Mutagenesis 29, 1–6, doi: 10.1093/mutage/get056 (2014).
- Sun X. L. & Weckwerth W. COVAIN: a toolbox for uni- and multivariate statistics, time-series and correlation network analysis and inverse estimation of the differential Jacobian from metabolomics covariance data. Metabolomics 8, S81–S93, doi: 10.1007/s11306-012-0399-3 (2012).
- Gomez-Meda B. C. et al.. Nuclear abnormalities in buccal mucosa cells of patients with type I and II diabetes treated with folic acid. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 797, 1–8, doi: 10.1016/j.mrgentox.2015.12.003 (2016).
- Castillo J. J., Mull N., Reagan J. L., Nemr S. & Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood 119, 4845–4850, doi: 10.1182/blood-2011-06-362830 (2012).
- El-Serag H. B., Hampel H. & Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369–380, doi: 10.1016/j.cgh.2005.12.007 (2006).
- Song S. S. et al.. Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis. PLoS One 10, 27, doi: e0134321 10.1371/journal.pone.0134321 (2015).
- Lee J. Y., Jeon I., Lee J. M., Yoon J. M. & Park S. M. Diabetes mellitus as an independent risk factor for lung cancer: A meta-analysis of observational studies. Eur. J. Cancer 49, 2411–2423, doi: 10.1016/j.ejca.2013.02.025 (2013).
- Fang H. et al.. Diabetes Mellitus Increases the Risk of Bladder Cancer: An Updated Meta-Analysis of Observational Studies. Diabetes Technol. Ther. 15, 914–922, doi: 10.1089/dia.2013.0131 (2013).
- Guraya S. Y. Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review. World J. Gastroenterol. 21, 6026–6031, doi: 10.3748/wjg.v21.i19.6026 (2015).
- Hardefeldt P. J., Edirimanne S. & Eslick G. D. Diabetes increases the risk of breast cancer: a meta-analysis. Endocrine-related cancer 19, 793–803, doi: 10.1530/erc-12-0242 (2012).
- Gong Y. H., Wei B. J., Yu L. & Pan W. J. Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: A meta-analysis of observational studies. Oral Oncol. 51, 332–340, doi: 10.1016/j.oraloncology.2015.01.003 (2015).
- Nathan D. M., Turgeon H. & Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50, 2239–2244, doi: 10.1007/s00125-007-0803-0 (2007).
- Wu L., Zhu J. J., Prokop L. J. & Murad M. H. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Sci Rep 5, 10, doi: 10.1038/srep10147 (2015).
- Holden S. E., Jenkins-Jones S., Morgan C. L., Schernthaner G. & Currie C. J. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes. Metab. 17, 350–362, doi: 10.1111/dom.12412 (2015).
- Biddinger S. B. & Ludwig D. S. The insulin-like growth factor axis: a potential link between glycemic index and cancer. Am. J. Clin. Nutr. 82, 277–278 (2005).
- Noto H., Goto A., Tsujimoto T., Osame K. & Noda M. Latest insights into the risk of cancer in diabetes. J. Diabetes Investig. 4, 225–232, doi: 10.1111/jdi.12068 (2013).
- Kowall B. & Rathmann W. & Kostev, K. Are Sulfonylurea and Insulin Therapies Associated With a Larger Risk of Cancer Than Metformin Therapy? A Retrospective Database Analysis. Diabetes Care 38, 59–65, doi: 10.2337/dc14-0977 (2015).
- Bolognesi C. et al.. Clinical application of micronucleus test in exfoliated buccal cells: A systematic review and metanalysis. Mutat. Res.-Rev. Mutat. Res. 766, 20–31, doi: 10.1016/j.mrrev.2015.07.002 (2015).
- Bonassi S. et al.. The HUman MicroNucleus project on eXfoLiated buccal cells (HUMNXL): The role of life-style, host factors, occupational exposures, health status, and assay protocol. Mutat. Res.-Rev. Mutat. Res. 728, 88–97, doi: 10.1016/j.mrrev.2011.06.005 (2011).
- Bonassi S. et al.. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis 28, 625–631, doi: 10.1093/carcin/bgl177 (2007).
- Ceppi M., Biasotti B., Fenech M. & Bonassi S. Human population studies with the exfoliated buccal micronucleus assay: Statistical and epidemiological issues. Mutat. Res.-Rev. Mutat. Res. 705, 11–19, doi: 10.1016/j.mrrev.2009.11.001 (2010).
- Cairns J. Mutation selection and natural-history of cancer. Nature 255, 197–200, doi: 10.1038/255197a0 (1975).
- Grindel A. et al.. Oxidative Stress, DNA Damage and DNA Repair in Female Patients with Diabetes Mellitus Type 2. PLoS One 11, e0162082, doi: 10. 1371/journal.pone.016082 (2016).
- Mullner E. et al.. Vegetables and PUFA-rich plant oil reduce DNA strand breaks in individuals with type 2 diabetes. Mol. Nutr. Food Res. 57, 328–338, doi: 10.1002/mnfr.201200343 (2013).
- Mullner E. et al.. Impact of polyunsaturated vegetable oils on adiponectin levels, glycaemia and blood lipids in individuals with type 2 diabetes: a randomised, double-blind intervention study. J. Hum. Nutr. Diet. 27, 468–478, doi: 10.1111/jhn.12168 (2014).
- D’Agostino R. B. et al.. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation 118, E86–E86, doi: 10.1161/circulationaha.108.190154 (2008).
- Tolbert P. E., Shy C. M. & Allen J. W. Micronuclei and other nuclear anomalies in buccal smears - methods development. Mutation Research 271, 69–77, doi: 10.1016/0165-1161(92)90033-i (1992).
Source: PubMed